Trial Profile
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir; Lopinavir/ritonavir
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms ROCKET-II
- Sponsors Gilead Sciences
- 15 Mar 2012 Planned number of patients changed from 85 to 160 as reported by European Clinical Trials Database record.
- 23 Jul 2010 Results presented at the 18th International AIDS Conference.
- 17 Dec 2009 Additional trial location identified as reported by ClinicalTrials.gov.